in vivo News and Research

RSS

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

Aeterna Zentaris Inc. today announced that a poster on its novel orally active anticancer Erk inhibitor, which includes AEZS-131, was presented at the 242nd American Chemical Society National Meeting held at the Colorado Convention Center in Denver, Colorado.

30 Aug 2011

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR), has signed an exclusive license with Amorfix Life Sciences Ltd. of Missisauga, Ontario for the use of their proprietary ProMIS technology in developing vaccines (active immunotherapy) for the treatment of diseases caused by the formation of misfolded prion.

29 Aug 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

Synovis Life Technologies third quarter net revenue increases 19% to record $21.0 million

Synovis Life Technologies, Inc., today reported its financial results for the fiscal third quarter ended July 31, 2011.

24 Aug 2011

Celldex announces key in vivo efficacy results of CDX-1135 in Dense Deposit Disease

Celldex Therapeutics, Inc. today announced key in vivo efficacy data for its CDX-1135 program from a collaboration with Drs. Richard Smith and Carla Nester at the University of Iowa.

24 Aug 2011

Study confirms tamoxifen is superior to fulvestrant in blocking estrogen

For the first time, researchers at Seattle Cancer Care Alliance have demonstrated the feasibility of using serial positron emission tomography (PET) scans, using a special estrogen-containing isotope, to confirm the relative effectiveness of estrogen-blocking and estrogen-depleting therapy in patients with metastatic breast cancer.

19 Aug 2011

Optical coherence tomography can distinguish between high and low risk pancreatic cysts

A team of researchers from four Boston-area institutions led by Nicusor Iftimia from Physical Sciences, Inc. has demonstrated for the first time that optical coherence tomography (OCT), a high resolution optical imaging technique that works by bouncing near-infrared laser light off biological tissue, can reliably distinguish between pancreatic cysts that are low-risk and high-risk for becoming malignant.

18 Aug 2011

Study finds increase in amount of brown fat among lean children

Researchers at Joslin Diabetes Center and Children's Hospital Boston have shown that a type of "good" fat known as brown fat occurs in varying amounts in children - increasing until puberty and then declining -- and is most active in leaner children.

12 Aug 2011

InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

11 Aug 2011

Researchers helps explain how the adult brain cleans out dead brain cells and produces new ones

Adult brains generate thousands of new brain cells called neurons each day; however only a small fraction of them survive. The rest die and are consumed by scavenger cells called phagocytes. Until now, scientists have not fully understood how this process works, which phagocytes are unique in the brain, and how the removal of dead neurons influences the production of new neurons.

10 Aug 2011

InVivo announces Platinum sponsorship to W2W spinal cord injury symposium

InVivo Therapeutics today announced the Company's Platinum level sponsorship of the 6th annual Working 2 Walk Science and Advocacy Symposium, which will take place October 16-18, 2011 in Rockville, Maryland.

9 Aug 2011

Innovative delivery systems and methods to treat breast cancer

In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).

4 Aug 2011

Celldex second quarter net loss increases to $10.2 million

Celldex Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2011. Celldex reported a net loss of $10.2 million, or $0.27 per share, for the second quarter of 2011 compared to a net loss of $9.5 million, or $0.30 per share, for the second quarter of 2010.

3 Aug 2011

Mathematical model predicts progress of tumors from early stages to metastasis

Researchers from the University of Miami (UM) and the University of Heidelberg in Germany have developed a mathematical model to understand and predict the progress of a tumor, from its early stages to metastasis, in hopes of creating highly personalized treatment strategies for patients who have cancer. The findings are published in Nature's new online journal Scientific Reports.

1 Aug 2011

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

1 Aug 2011

Myb protein suppression can help eliminate acute myelogenous leukemia

A team of scientists at Cold Spring Harbor Laboratory (CSHL) has laid bare the mechanism behind a phenomenon called oncogene addiction in mice suffering from a form of leukemia that mimics acute myelogenous leukemia (AML) in humans.

1 Aug 2011

New protein discovery could help develop intracellular biologic drugs

Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins-.

29 Jul 2011

Oral chicken interferon-alpha may significantly reduce influenza infection

Avian influenza virus is a threat to the commercial chicken industry and, with its recent rapid spread across China, has also shown the ability for transmission from chickens to humans and other mammals.

29 Jul 2011

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Ipsen today announced that its partner Inspiration Biopharmaceuticals, Inc. presented data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia.

28 Jul 2011

New LEAP technique can restore heart rhythm in patients with atrial fibrillation

A high-amplitude, and often painful, electrical shock is the only currently available method for treating certain cases of chronic cardiac arrhythmia. But now a new technique using much weaker impulses has been developed by an international team of physicists and cardiologists, including Alain Pumir, CNRS researcher at the ENS Lyon physics laboratory.

28 Jul 2011

in vivo News and Research

Results of Aeterna Zentaris' AEZS-131 anticancer Erk inhibitor presented at ACS 2011 meeting

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Synovis Life Technologies third quarter net revenue increases 19% to record $21.0 million

Celldex announces key in vivo efficacy results of CDX-1135 in Dense Deposit Disease

Study confirms tamoxifen is superior to fulvestrant in blocking estrogen

Optical coherence tomography can distinguish between high and low risk pancreatic cysts

Study finds increase in amount of brown fat among lean children

InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

Researchers helps explain how the adult brain cleans out dead brain cells and produces new ones

InVivo announces Platinum sponsorship to W2W spinal cord injury symposium

Innovative delivery systems and methods to treat breast cancer

Celldex second quarter net loss increases to $10.2 million

Mathematical model predicts progress of tumors from early stages to metastasis

Femta files IND with FDA for FM101 monoclonal antibody against RA

Myb protein suppression can help eliminate acute myelogenous leukemia

New protein discovery could help develop intracellular biologic drugs

Oral chicken interferon-alpha may significantly reduce influenza infection

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

New LEAP technique can restore heart rhythm in patients with atrial fibrillation

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News